Document is current
Any future updates will be listed below
-
Authors
Davtyan, Hayk http://orcid.org/0000-0001-8554-6456
Hovakimyan, Armine
Kiani Shabestari, Sepideh
Antonyan, Tatevik
Coburn, Morgan A.
Zagorski, Karen
Chailyan, Gor
Petrushina, Irina
Svystun, Olga
Danhash, Emma
Petrovsky, Nikolai
Cribbs, David H.
Agadjanyan, Michael G.
Blurton-Jones, Mathew
Ghochikyan, Anahit
-
Funding
Funding for this research was provided by:
National Institutes of Health (R01-NS050895, R01-AG020241, U01-AG060965, R21-NS101504, R01-AG061895, RF1-AG048099, R01-AG055524, R01-AG056303, P50-AG016573, U01-AI061142, HHS-N272201400053C, HHS-N272200800039C)
- License Information
-
More Information
Article History
Received: 21 June 2019
Accepted: 11 November 2019
First Online: 17 December 2019
Ethics approval and consent to participate
: All animal studies are conducted in accordance with the NIH, American Physiological Society, and University of California, Irvine Animal Care Guidelines. The University of California, Irvine, animal assurance number is A3416-01.
: Not applicable
: MGA and AG are co-founders of Capo Therapeutics that licensed MultiTEP vaccine platform technology from the Institute for Molecular Medicine. NP is a founder of Vaxine that developed Advax<sup>CpG</sup> adjuvant. The remaining authors declare that they have no competing interests.
